GMAB Stock Overview
Develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for GMAB from our risk checks.
Genmab A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 1,715.00 |
| 52 Week High | DKK 2,598.00 |
| 52 Week Low | DKK 1,691.00 |
| Beta | 0.86 |
| 11 Month Change | -5.90% |
| 3 Month Change | -4.99% |
| 1 Year Change | -32.19% |
| 33 Year Change | -38.31% |
| 5 Year Change | 22.50% |
| Change since IPO | 636.05% |
Recent News & Updates
The Price Is Right For Genmab A/S (CPH:GMAB)
Sep 19
We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated
Aug 22Recent updates
The Price Is Right For Genmab A/S (CPH:GMAB)
Sep 19We Think Genmab's (CPH:GMAB) Solid Earnings Are Understated
Aug 22Genmab A/S' (CPH:GMAB) Price In Tune With Earnings
Apr 02We Think Genmab A/S' (CPH:GMAB) CEO Compensation Package Needs To Be Put Under A Microscope
Mar 07Genmab's (CPH:GMAB) Conservative Accounting Might Explain Soft Earnings
Feb 21Is Genmab A/S (CPH:GMAB) Trading At A 50% Discount?
Nov 13Is Now The Time To Put Genmab (CPH:GMAB) On Your Watchlist?
Jun 19Is There An Opportunity With Genmab A/S' (CPH:GMAB) 44% Undervaluation?
May 29With EPS Growth And More, Genmab (CPH:GMAB) Makes An Interesting Case
Mar 18Genmab A/S (CPH:GMAB) Shares Could Be 50% Below Their Intrinsic Value Estimate
Feb 27Here's Why We Think Genmab (CPH:GMAB) Is Well Worth Watching
Dec 17Shareholder Returns
| GMAB | DK Biotechs | DK Market | |
|---|---|---|---|
| 7D | -4.7% | -3.8% | -5.0% |
| 1Y | -32.2% | -1.9% | 23.3% |
Return vs Industry: GMAB underperformed the Danish Biotechs industry which returned -1.9% over the past year.
Return vs Market: GMAB underperformed the Danish Market which returned 23.3% over the past year.
Price Volatility
| GMAB volatility | |
|---|---|
| GMAB Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 7.7% |
| Market Average Movement | 4.3% |
| 10% most volatile stocks in DK Market | 9.1% |
| 10% least volatile stocks in DK Market | 2.4% |
Stable Share Price: GMAB has not had significant price volatility in the past 3 months.
Volatility Over Time: GMAB's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 2,526 | Jan G.J. de Winkel | www.genmab.com |
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies.
Genmab A/S Fundamentals Summary
| GMAB fundamental statistics | |
|---|---|
| Market cap | DKK 108.91b |
| Earnings (TTM) | DKK 5.54b |
| Revenue (TTM) | DKK 19.02b |
19.7x
P/E Ratio5.7x
P/S RatioIs GMAB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GMAB income statement (TTM) | |
|---|---|
| Revenue | DKK 19.02b |
| Cost of Revenue | DKK 580.00m |
| Gross Profit | DKK 18.44b |
| Other Expenses | DKK 12.90b |
| Earnings | DKK 5.54b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 06, 2024
| Earnings per share (EPS) | 87.24 |
| Gross Margin | 96.95% |
| Net Profit Margin | 29.13% |
| Debt/Equity Ratio | 0% |
How did GMAB perform over the long term?
See historical performance and comparison